Table 1.

Most relevant repurposed antiviral drugs against SARS-CoV-2.

Antiviral drug	Approved target disease	Drug target	COVID-19 clinical trial reference
Favipiravir	Influenza virus	Virus RdRp	Doi et al., 2020
Hydroxychloroquine	Malaria	Hemozoin biocrystallization	Axfors et al., 2021; WHO Solidarity Trial Consortium, 2021
Ivermectin	Antiparasitic	Glutamate-gated chloride channels	Baker and Reardon, 2021; Popp et al., 2021
Interferon beta-1a	Multiple sclerosis	Reduce inflammation	WHO Solidarity Trial Consortium, 2021
Lopinavir	HIV-1	Virus protease	Cao et al., 2020; WHO Solidarity Trial Consortium, 2021
Remdesivir	SARS-CoV-2	Virus RdRp	Wang et al., 2020; WHO Solidarity Trial Consortium, 2021